surmount-1 trial tirzepatide obesity without diabetes SURMOUNT-4 results just published in @JAMA_current 🛑Stopping #tirzepatide leads to regain of the majority of the lost weight. Is this a surprising result ⁉️ No #Obesity is a chronic disease and requires Gastrointestinal tolerability and weight reduction

2022 Dec 12

There are few human studies that have examined key outcomes such as increased vitality, reduction in all causes of death, prolonged health, and lifespan

With a growing list of serious symptoms after taking Ozempic, thousands are suing Novo Nordisk for its failure to adequately warn consumers about multiple side effects of GLP-1 drugs, including vision side effects

Rybelsus (oral semaglutide) may be covered for blood sugar control

Get in touch with us today to schedule your consultation

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)